FOLD Amicus Therapeutics: Operating Profitability

Amicus Therapeutics - graphic logo of issuer FOLD

The operating margin of Amicus Therapeutics (FOLD) is based on the dynamics of patient recruitment for rare pathologies and patent support, with the indicator recorded at 5.40. Current profitability is constrained by challenges in securing insurance reimbursements for new Pompe disease treatment methods. However, the company possesses absolute pricing power, creating unique life-saving drugs to combat severe metabolic failures.

FOLD: Amicus Therapeutics, Inc. Operating Margin 07/04/2022 - 05/09/2026

FOLD (Amicus Therapeutics): analytical breakdowns and indicator data

- price and consensus price forecast:
Comprehensive company analysis:Amicus Therapeutics Inc
Finished products of Amicus Corp

Amicus Therapeutics (FOLD) monetizes the creation of a closed therapeutic environment for patients with rare diseases, where the ecosystem's efficiency directly impacts profitability. The ratio of operating result to revenue, displayed as the operating income margin on GURU.Markets, measures the business's ability to generate cash flow before financial expenses, allowing investors to assess the fundamental stability and scalability of the company's development model.